Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes

Affiliations

• ¹ Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
• ² Lipid Metabolism Unit, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA.
• ³ Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan hnabe@kumamoto-u.ac.jp tomaru@gpo.kumamoto-u.ac.jp.
• ⁴ Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
• ⁵ Diabetes Care Center, Jinnouchi Hospital, Kumamoto, Japan.
• ⁶ Department of Nephrology, Akebono Clinic, Kumamoto, Japan.
• ⁷ Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
• ⁸ Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan.
• ⁹ Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.